Comparing Fosaprepitant and Metoclopramide for Nausea and Vomiting
This study is looking at two medicines, fosaprepitant and metoclopramide, to see which one works better at treating nausea and vomiting in the emergency room. Fosaprepitant works by blocking a specific signal in the brain that causes vomiting. Metoclopramide is a common treatment. We want to find out if fosaprepitant is more effective and has fewer side effects than metoclopramide. You might be able to join if you are an adult (18 years or older) coming to the emergency room for nausea and/or vomiting. We will be looking to see if your nausea and vomiting improve within 2 hours after getting the medicine, and if any new symptoms develop. The current status of this study is unclear, but it plans to enroll 212 people.
- Study design
- This is a double-blind, randomized study comparing two treatments. This means neither you nor your doctor will know which medicine you receive. The study plans to include 212 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your nausea and vomiting relief and any new symptoms will be checked 2 hours after you receive the study medicine.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
At a glance
Conditions
NCT06740812
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Montefiore Medical Center
The Bronx, New Yorkstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Benjamin Friedman, MD · PRINCIPAL_INVESTIGATOR · Montefiore Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Sustained Nausea and Vomiting (NV) Relief2 hours (assessed at the 2-hour mark after administration of the intervention)
The primary efficacy outcome for this study will be sustained relief from NV at 2 hours following medication administration. Sustained relief from NV will be determined by the intensity of nausea reported by patients following administration of antiemetic. Intensity of nausea will be reported as either "None", "Mild", "Moderate" or "Severe." The number/percentage of patients reporting each degree of nausea intensity at 2 hours will be summarized by study arm. Sustained relief of NV requires a patient to present with a nausea intensity of either "Severe" or "Moderate," which is then reduced by treatment to at least "Mild" or None," within 2 hours of medication administration without the use of any rescue medication. Patients who do not report an initial nausea intensity of either "Severe" or "Moderate" will not be assessed as they are not eligible for the study.
- Development of New Symptom2 hours (assessed at the 2-hour mark after administration of the intervention)
The primary tolerability outcome for this study will be the onset of any new symptoms within 2 hours after medication administration. Onset of symptoms will be assessed by asking patients if they developed any new symptoms after administration of the investigational medication. Symptoms will be elicited using an open-ended format. Patients who confirmed that they had experienced new symptoms will be asked to grade the severity of the new symptom(s) using the descriptors "Mild", "Moderate", or "Severe". The frequency and intensity of new symptoms will be summarized by study arm using basic descriptive statistics.